Rani Therapeutics Reports Positive Initial Phase 1a Data for RT-114 in Obesity
Rani Therapeutics (RANI) reported positive initial phase 1a data for RT-114 showing oral bioavailability exceeded that of a matched subcutaneous dose in healthy volunteers, the company said Wednesday.Oral RT-114 achieved systemic exposure of more than 150% relative to a matched 12-milligram subcutaneous dose of PG-102, Rani Therapeutics said.No serious adverse events were reported, and treatment-related adverse events were mild and consistent with the known profile of GLP-1/GLP-2 dual agonists, the company said.Rani Therapeutics also said it has expanded the phase 1a study with an additional cohort to further evaluate the oral-to-subcutaneous pharmacokinetic relationship before starting a planned phase 1b repeat-dose study in patients with obesity later this year.Data from the phase 1b study are expected in 2027, Rani Therapeutics said.Shares of the company were 6.5% higher in premarket trading.
